Zydus FDA Monday, October 19, 2026 +0.30 Positive

FDA Approves ROMIDEPSIN — Zydus Lifesciences Limited

Zydus Lifesciences Limited announced the FDA approval of Romidepsin for the treatment of cutaneous T-cell lymphoma. This regulatory green light is expected to bolster the company's portfolio and intensify competition in the oncology generic market.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed